title: Metabolic complications and selected cytokines in HIV-infected individuals.
abstract: BACKGROUND
  Human immunodeficiency virus (HIV)-infected individuals are at a higher risk of developing metabolic disturbances. The pathogenesis of these complications is complex and not fully explored.
  
  
  OBJECTIVE
  The aim of the study was to investigate the effect of HIV infection and antiretroviral (ARV) therapy on the development of metabolic changes and adipocytokine concentrations. The analysis of the differences in the investigated parameters among lipodystrophic and nonlipodystrophic patients was also performed.
  
  
  METHODS
  A total of 42 HIV‑infected patients on ARV therapy (HIV[+]ARV[+]), 13 HIV‑infected ARV naive patients (HIV[+]ARV[-]), and 20 healthy controls were included in the study. A lipid profile, fasting free fatty acids (FFAs), glucose, insulin, and insulin resistance (homeostasis model assessment of insulin resistance--HOMA‑IR) were tested. Serum concentrations of tumor necrosis factor α (TNF‑α), interleukin 6 (IL‑6), adiponectin, leptin, and fatty acid-binding protein 4 (FABP4) were determined.
  
  
  RESULTS
  Increased FFA levels were observed in HIV(+)ARV(-) patients. HIV(+)ARV(+) patients had significantly higher triglycerides and insulin level compared with controls. HOMA‑IR showed a tendency to be higher in HIV(+)ARV(+) patients compared with the other study groups. The ARV therapy longer than 2 years resulted in more pronounced metabolic abnormalities. HIV infection itself had a significant effect on inflammation expressed by elevated TNF‑α and IL‑6 levels. We did not observe differences in adiponectin and FABP4 concentrations among the study groups, while the leptin concentration was significantly lower in HIV‑infected lipodystrophic than in nonlipodystrophic patients.
  
  
  CONCLUSIONS
  HIV infection induces lipid disorders, especially associated with fatty acid turnover augmented by ARV therapy. Compared with FABP4, leptin is a better biological marker of metabolic complications in HIV‑infected patients.
authors.forename: Monika
authors.initials: M
authors.lastname: Bociąga-Jasik
authors.forename: Anna
authors.initials: A
authors.lastname: Polus
authors.forename: Joanna
authors.initials: J
authors.lastname: Góralska
authors.forename: Agnieszka
authors.initials: A
authors.lastname: Śliwa
authors.forename: Urszula
authors.initials: U
authors.lastname: Raźny
authors.forename: Anna
authors.initials: A
authors.lastname: Zdzienicka
authors.forename: Aleksander
authors.initials: A
authors.lastname: Garlicki
authors.forename: Tomasz
authors.initials: T
authors.lastname: Mach
authors.forename: Aldona
authors.initials: A
authors.lastname: Dembińska-Kieć
mesh_terms: D052242:Adiponectin / Q000097:blood*; D000273:Adipose Tissue / Q000378:metabolism; D000328:Adult; D044966:Anti-Retroviral Agents / Q000627:therapeutic use; D008078:Cholesterol, LDL / Q000097:blood; D016207:Cytokines / Q000097:blood*; D050556:Fatty Acid-Binding Proteins / Q000097:blood*; D005260:Female; D044882:Glucose Metabolism Disorders / Q000097:blood / Q000209:etiology*; D015658:HIV Infections / Q000097:blood* / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D007333:Insulin Resistance; D008297:Male; D055815:Young Adult
chemical_list: D052242:Adiponectin; D044966:Anti-Retroviral Agents; D008078:Cholesterol, LDL; D016207:Cytokines; C493410:FABP4 protein, human; D050556:Fatty Acid-Binding Proteins